{"title":"[新诊断急性髓性白血病患者 DTA 基因突变的预后价值]。","authors":"Hui-Juan Chen, Yang Cao, Ying-Jie Miao, Yi-Fang Zhou, Yue Liu, Wei-Ying Gu","doi":"10.19746/j.cnki.issn.1009-2137.2024.04.003","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the prognostic significance of DTA (<i>DNMT3A, TET2, ASXL1</i> ) gene mutations in patients with non-M3 acute myeloid leukemia (AML).</p><p><strong>Methods: </strong>The clinical data of 180 newly diagnosed AML patients hospitalized in the First People's Hospital of Changzhou from January 2018 to April 2022 were retrospectively analyzed. Next-generation sequencing technology was used to detect 150 gene mutations in the patients, and log-rank tests and Cox regression models were used to analyze the prognostic factors.</p><p><strong>Results: </strong>DTA gene mutations were detected in 83 (46.1%) of 180 AML patients. Compared to patients without DTA mutations, patients with DTA mutations were significantly older (<i>P</i> < 0.001). The median overall survival (OS) time and disease-free survival (DFS) time in the DTA mutation group were significantly shorter than those in the group without DTA mutation (both <i>P</i> < 0.05). Multivariate analysis showed that age ≥ 60 years (<i>P</i> < 0.001), with DTA mutation (<i>P</i> =0.018), and intermediate-risk (relative to favorable-risk) (<i>P</i> =0.005) were independent risk factors for OS in AML patients.</p><p><strong>Conclusion: </strong>AML patients with DTA mutations are relatively older, with shorter median OS time and DFS time, and poor prognosis.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Prognostic Value of DTA Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia].\",\"authors\":\"Hui-Juan Chen, Yang Cao, Ying-Jie Miao, Yi-Fang Zhou, Yue Liu, Wei-Ying Gu\",\"doi\":\"10.19746/j.cnki.issn.1009-2137.2024.04.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To investigate the prognostic significance of DTA (<i>DNMT3A, TET2, ASXL1</i> ) gene mutations in patients with non-M3 acute myeloid leukemia (AML).</p><p><strong>Methods: </strong>The clinical data of 180 newly diagnosed AML patients hospitalized in the First People's Hospital of Changzhou from January 2018 to April 2022 were retrospectively analyzed. Next-generation sequencing technology was used to detect 150 gene mutations in the patients, and log-rank tests and Cox regression models were used to analyze the prognostic factors.</p><p><strong>Results: </strong>DTA gene mutations were detected in 83 (46.1%) of 180 AML patients. Compared to patients without DTA mutations, patients with DTA mutations were significantly older (<i>P</i> < 0.001). The median overall survival (OS) time and disease-free survival (DFS) time in the DTA mutation group were significantly shorter than those in the group without DTA mutation (both <i>P</i> < 0.05). Multivariate analysis showed that age ≥ 60 years (<i>P</i> < 0.001), with DTA mutation (<i>P</i> =0.018), and intermediate-risk (relative to favorable-risk) (<i>P</i> =0.005) were independent risk factors for OS in AML patients.</p><p><strong>Conclusion: </strong>AML patients with DTA mutations are relatively older, with shorter median OS time and DFS time, and poor prognosis.</p>\",\"PeriodicalId\":35777,\"journal\":{\"name\":\"中国实验血液学杂志\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国实验血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.04.003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.04.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
[Prognostic Value of DTA Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia].
Objective: To investigate the prognostic significance of DTA (DNMT3A, TET2, ASXL1 ) gene mutations in patients with non-M3 acute myeloid leukemia (AML).
Methods: The clinical data of 180 newly diagnosed AML patients hospitalized in the First People's Hospital of Changzhou from January 2018 to April 2022 were retrospectively analyzed. Next-generation sequencing technology was used to detect 150 gene mutations in the patients, and log-rank tests and Cox regression models were used to analyze the prognostic factors.
Results: DTA gene mutations were detected in 83 (46.1%) of 180 AML patients. Compared to patients without DTA mutations, patients with DTA mutations were significantly older (P < 0.001). The median overall survival (OS) time and disease-free survival (DFS) time in the DTA mutation group were significantly shorter than those in the group without DTA mutation (both P < 0.05). Multivariate analysis showed that age ≥ 60 years (P < 0.001), with DTA mutation (P =0.018), and intermediate-risk (relative to favorable-risk) (P =0.005) were independent risk factors for OS in AML patients.
Conclusion: AML patients with DTA mutations are relatively older, with shorter median OS time and DFS time, and poor prognosis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
